Correlation between Slope 2 in Clot Waveform Analysis of Activated Partial Thromboplastin Time with Factor VIII Activity in Hemophilia A
DOI:
https://doi.org/10.24293/ijcpml.v28i3.1869Keywords:
Factor VIII activity, hemophilia A, slope 2 of aPTTAbstract
Hemophilia A is an inherited factor VIII deficiency disease, related to X chromosome. Diagnosis of Hemophilia A is made based on Factor VIII assay. Nowadays, Hemophilia A therapy is by giving factor VIII concentrate, so that monitoring of this therapy must be done by examine Factor VIII activity, but examination of Factor VIII activity is currently still limited in facilities and quite expensive. One of activated partial thromboplastin time (aPTT) optical methods can provide information about every stage of coagulation through clot waveform analysis. Factor VIII activity can describe in slope 2 of clot waveform analysis, which deficiency of factor VIII will cause slope 2 slighter than normal, because the clot form is not optimal and the light transmission recorded at clot waves do not decrease maximally. The aim of this study was to analyze the correlation between slope 2 on the clot waveform analysis of the optical method on aPTT test with Factor VIII activity in hemophilia A subjects. This was a correlative observational study cross sectional study, conducted at Hasan Sadikin General Hospital Bandung in August 2018-September 2019. The subjects were member of Hemophilia A sufferers of West Java Hemophilia Society. The research subjects were assesed for Factor VIII activity and optical method of aPTT. Slope 2 calculated from the clot waveform analysis that formed in aPTT examination. This study involved 43 subjects, with a median age of 6 years, an age range of 1-45 years, and 51.2% of patients aged 6-17 years. The results of Factor VIII activity in this study had a median 0% with a range 0-25.9%, and the value of slope 2 had a median 1.0%T/sec with a range 0.5-3.5%T/sec. The correlation test between slope 2 and Factor VIII activity with 95% confidence interval using Spearman's correlation test showed very strong positive correlation which statistically significant (r = 0.854 and p <0.001). Conclusion: there was a statistically significant very strong positive correlation between slope 2 on the clot waveform analysis of aPTT optical method test with the activity of Factor VIII in Hemophilia A.
Downloads
References
Bertamino M, Riccardi F, Banov L, Svahn J, Molinari AC. Hemophilia in the pediatric age. J Clin Med, 2017; 6(54): 1-13.
Schwartz SL. Disorder of plasma clotting factor. In: Harmening DM, editor. Clinical hematology and
th fundamentals of hemostasis. 5 Ed., Philadelphia, FA Davis Company, 2009; 618-20.
Castaman G, Matino D. Hemophilia A, and B: Molecular and clinical similarities and differences.
Hematological, 2019; 104(9): 1-8.
Peyvandi F, Garagiola I, Young G. The past and future of hemophilia: Diagnosis, treatments, and its
complications. The Lancet, 2016; 15: 1-11.
Swystun LL, James PD. Genetic diagnosis in hemophilia and von Willebrand disease. Blood Reviews, 2016; 31(1): 47-56.
Benson G, Auerswald G, Dolan G, Duffy A, Hermans C, et al. Diagnosis and care of patients with mild
hemophilia: Practical recommendation for clinical management. Blood Transfus, 2018; 16(6): 535-44.
Vulpen LFD, Holstein K, Martinoli C. Joint disease in hemophilia: Pathophysiology, pain, and imaging.
Haemophilia, 2018; 24: 44-9.
Roswati MN. Heterogeneity of hemophilia A genetic and environmental factors on the development of factor VIII inhibitors. Asian Journal of Medicine and Health Sciences, 2020; 3: 10-9.
Majid Z, Tahir F, Qadar LT, Shaikh MY, Mustafa S, et al. Hemophilia A with a rare presentation of hemarthrosis and arthropathy involving multiple joints in a young male child. Cureus, 2019; 11(4): 1-7.
Kizilocak H, Young G. Diagnosis and treatment of hemophilia. Clinical Advances in Hematology &
Oncology, 2019; 17(6): 344-51.
Seaman CD, Xavier F, Ragni MV. Hemophilia A (factor VIII deficiency). Hemato Oncol Clin North Am, 2021; 35(6): 1117-29.
Shima M, Thachil J, Nair SC, Srivastava A. Towards standardization of clot waveform analysis and
recommendation for its clinical application. J Thromb Haemost, 2013; 11: 1417-20.
Matsumoto T, Nogami K, Tabuchi Y, Yada K, Ogiwara K, et al. Clot waveform analysis using CS-2000i
distinguishes between very low and absent levels of factor VIII activity in patients with severe hemophilia A. Haemophilia, 2017; 23: 427-35.
Seven PO, Depasse F. Clot waveform analysis: Where do we stand in 2017? Int J Lab Hem, 2017; 39: 561-68.
Siegemund T, Scholz U, Schobess R, Siegemund A. Clot waveform analysis in patients with hemophilia A. Hämostaseologie, 2014; 34: S48-S62.
Shima M, Matsumoto T, Kazuyoshi F, Kubota Y, Tanaka I, et al. The utility of Activated Partial Thromboplastin Time (APTT) clot waveform analysis in the investigation of hemophilia A patients with very low levels of factor VIII activity (FVIII:C). Thromb Haemost, 2002; 87: 436-41.
Prasetyawaty F, Sukrisman, L, Setyohadi B, Setiati S, Prasety M. Prediktor kualitas hidup terkait kesehatan pada penderita hemofilia dewasa di Rumah Sakit Cipto Mangunkusumo. Jurnal Penyakit Dalam Indonesia, 2016; 3(3): 116-24.
Payne AB, Ghaji N, Mehal JM, Chapman C, Haberling DL, et al. Mortality trends and causes of death in
persons with hemophilia in the United States 1999-2014. Blood, 2017; 130(1): 755-57.
Kloosterman F, Zwagemaker AF, Abdi A, Gouw S, Castaman G et al. Hemophilia management: Huge
impact of a tiny difference. Res Pract Thromb Haemost, 2020; 4: 337-85.
World Federation of Hemophilia. Annual global survey 2017. 2018. Available from: http://www1.wfh.
org/publications/files/pdf-1714.pdf (accessed September 5, 2019).
Shima M, Matsumoto T, Ogiwara K. New assays for monitoring hemophilia treatment. Haemophilia,
; 14(3): 83-92
Downloads
Submitted
Accepted
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
